Mixed
Glatiramer acetate: reduce relapses and new lesions in relapsing MS
Trial timeline
Trial start year. Dot size reflects participants where reported. Only trials that count towards the status are shown.
relapsing MS · Glatiramer acetate
Controlled trials disagree.
1 trial(s) stopped for safety reasons.
- Trials
- 18
- Running now
- 1
- Controlled phase 2/3 trials
- 5
- People in controlled trials
- 3659
Deciding trials (phase 3): 2 met, 1 did not.
Other linked trials: 15
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
- A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMSdecides the statusMet main goal
Phase 3 · 2019 · Placebo-controlled · MSFT-NCT04121221
Adjusted ARR was lower in patients treated with GA Depot compared to placebo (0.18, 95% confidence interval [CI] = 0.14 to 0.3 vs 0.26, 95% CI = 0.21 to 0.32, 30.1% relative risk reduction, p = 0.0066).
Read by software from the paper's abstract Phase 3 · 2012 · Placebo-controlled · MSFT-NCT01578785
Phase 3 · 2010 · Placebo-controlled · MSFT-NCT01067521
- Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRxdecides the statusMissed main goal
Phase 3 · 2005 · Placebo-controlled · MSFT-NCT00211887
Combination IFN+GA was not superior to the better of the single agents (GA) in risk of relapse.
Read by software from the paper's abstract
Other linked trials: 15
These linked trials do not set the status.
- Full RespondersStopped, other reason
Phase 4 · 2022 · Not randomised
- Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMSStopped: safety
Phase 4 · 2004 · Compared with interferon beta-1a, interferon beta-1b
- BECOMEMet main goal
Phase 4 · 2003 · Not randomised
- TWINSOngoing
Phase 3 · 2025 · Not randomised
Phase 3 · 2018 · Not randomised
- Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple SclerosisResult in a paper, not read yet
Phase 3 · 2013 · Compared with glatiramer acetate
- GATEShown as good as comparator
Phase 3 · 2011 · Compared with glatiramer acetate
- Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).Missed main goal
Phase 3 · 2006 · Not randomised
- FORTEStopped, other reason
Phase 3 · 2006 · Compared with glatiramer acetate
- GATEWAYIIMet main goal
Phase 2 · 2012 · Placebo-controlled
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Status changed from Being tested to Mixed
- 2026-10-28Trials: 17 → 18
- 2026-10-28Status changed from Results pending to Being tested
- 2026-10-27First listed as Results pending
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error